Outlining the Evolving Efficacy and QOL Outcomes Associated With ADT in Prostate Cancer

Advances in ADT Personalization and Molecular Imaging Shape Updated NCCN Prostate Cancer Recommendations: With Daniel Spratt, MD

ByDaniel Eidelberg Spratt, MD

November 25th 2025

Daniel Spratt, MD, discusses key updates to the National Comprehensive Cancer Network Guidelines for prostate cancer.

Neal Shore, MD, FACS, medical director, Carolina Urologic Research Center

Ongoing ADT Use and Research Emphasizes the Importance of Shared Decision-Making in Prostate Cancer Care: With Neal Shore, MD, FACS

ByNeal Shore, MD, FACS

October 31st 2025

Dr Shore discusses the use of ADT in patients with prostate cancer, as well as toxicities and quality-of-life complications associated with these agents.

Tanya B. Dorff, MD, section chief, Genitourinary Disease Program, professor, Department of Medical Oncology & Therapeutics Research, City of Hope

Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD

ByTanya B. Dorff, MD

September 2nd 2025

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma

Oncology Fellows Presents a New Drug Cheat Sheet for Fellows

Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC

Northwestern Medicine Surgeons Develop a Total Artificial Lung System to Keep a Patient Alive for 48 Hours After Removing Both Lungs, Enabling a Double-Lung Transplant